Bristol Myers Squibb: A Reliable Dividend Pharma Giant
Pays steady dividends and develops new treatments for cancer and Alzheimer’s.
MaxDividends Mission: Helping people build growing passive income, retire early, and live off dividends.
For dividend investors seeking opportunities with strong growth potential, MaxDividends Stock Ideas offers a daily, in-depth look at companies worth considering for a dividend portfolio.
🔓 Request Free Early Access to the MaxDividends App
Intro
💡 Invest in companies you believe in - W. Buffett
Bristol Myers Squibb (BMY) is a major pharmaceutical company with a strong product lineup, especially in oncology. Despite competition and expiring patents on some drugs, it maintains stable dividends and actively develops new therapies. Promising projects include BMS-986446 for Alzheimer’s and other treatments for cancer and HIV, making the company attractive for long-term investors.
History of the Company
Bristol Myers Squibb’s history began with two separate pharmaceutical pioneers:
Bristol‑Myers Company (1887): William McLaren Bristol and John Ripley Myers invested in a small drug firm in Clinton, New York. The company initially produced consumer products such as laxatives and toothpaste and gradually expanded into pharmaceuticals.
E.R. Squibb Company (1858): Edward Robinson Squibb founded his own pharmaceutical business, focusing on producing high-quality medicines and innovations in drug manufacturing.
In 1989, the two companies merged to form Bristol Myers Squibb, creating one of the world’s largest biopharmaceutical companies. Since then, the company has focused on discovering and developing treatments for serious diseases, including cancer, cardiovascular conditions, and immunological disorders.
Dividends
Bristol Myers Squibb (BMY) is known for its strong and reliable dividend program, making it attractive for income-focused investors. The company currently offers a dividend yield of 4.63% and an annual dividend of $2.52 per share, with the next payment scheduled for February 2.
BMY has a track record of increasing dividends for 17 consecutive years, and its annualized 5-year dividend growth rate is 7.91%, reflecting steady, long-term growth. The dividend payout ratio stands at 85.14%, showing a solid commitment to returning value to shareholders while balancing reinvestment in its business.
🟢 Current dividend yield of 4.54% is significantly higher than its 10-year average of 3.30%, highlighting the stock’s strong income potential.
In the MaxDividends app, open the 10-year yield band and set a price/yield alert to ping you when it drifts back into your buy zone.
🟢 Current Payout Ratio 83.7%
This is a fairly high level — Bristol Myers Squibb still covers dividends, but leaves less room for growth and reinvestment. A payout Ratio of about 84% signals moderate dividend security: dividends are stable, but the company should carefully plan capital expenditures. In the MaxDividends app, check the Payout Safety and forecast of future payouts to assess sustainability before purchasing or reinvesting.
Key Institutional Investors in Bristol Myers Squibb
Bristol Myers Squibb (BMY) is backed by major institutional investors, highlighting strong confidence from large asset managers:
The Vanguard Group Inc.: Holds approximately 9–10% of the company’s shares.
BlackRock, Inc.: Owns around 8–9% of outstanding stock.
State Street Global Advisors: Holds roughly 4–5% of shares.
Other notable institutional investors include Charles Schwab Investment Management, J.P. Morgan Asset Management, Capital International Investors, and Geode Capital Management, each holding smaller but meaningful stakes.
What Makes Bristol Myers Squibb Stand Out?
Bristol Myers Squibb (NYSE: BMY)
Financial Score: 92 / 99 ⭐️⭐️⭐️⭐️⭐️
Industry: Drug Manufacturers - General
Dividend Increase - 17 Years
👉 Learn more about Financial Score
Bristol Myers Squibb (NYSE: BMY) is a leading global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for serious diseases such as cancer, immunological disorders and cardiovascular conditions.
Its strength lies in a diversified product portfolio that includes major therapies like Opdivo (immuno‑oncology), Eliquis (anticoagulant) and growing newer treatments that help stabilize revenue despite generic competition.
BMS combines the scale of a big pharma with a biotech‑like drive for science, investing heavily in R&D while expanding through strategic deals and partnerships to fuel its pipeline and future growth.
This blend of established blockbuster drugs, a robust development pipeline and commitment to scientific innovation helps Bristol Myers Squibb stand out in the drug‑makers industry.
Bristol Myers Squibb - Quick MaxDividends Team Overview
🟢 According to the latest reports, the company is profitable.
🟢 One of the key strengths is consistent sales growth — a positive sign
for future development.
🟢 The company’s operating profit has been trending up over the past few years — it’s gaining market presence and expanding its footprint.
🟢 Earnings are increasing on a per-share basis. That’s good news for both reinvestment and potential dividends.
⚪️ Management appears capable and income is generally positive, but the business still faces occasional setbacks.Historical Context
Bristol Myers Squibb has a long history of regular dividend payments and consistent increases. Over the past decade, the company has steadily grown its payouts, reinforcing its reputation as a reliable income stock.
In 2015, BMY’s quarterly dividend was approximately $0.50 per share, and by 2016, it had increased to about $0.54 per share (+8% growth). In 2025, the company declared a quarterly dividend of $0.63 per share for Q1, reflecting its commitment to long-term shareholder returns and a proven track record of dividend growth.
With MaxDividends App, it’s easier than ever to access top dividend companies, track your results, and explore new dividend ideas.
Financial Statement
👉 Looking at Bristol Myers Squibb’s recent numbers, the company has shown steady revenue growth and solid operational results, driven by strong demand for key medicines, especially in its Growth Portfolio. In full‑year 2024, BMY reported $48.3 billion in revenue, up about 7 % from 2023, with growth portfolio sales such as Reblozyl, Breyanzi and Opdivo rising significantly.
Non‑GAAP earnings per share for 2024 were $1.15, reflecting profitability after adjustment for one‑time charges. In the fourth quarter of 2024 alone, the company generated $12.3 billion in revenue, an 8 % increase year‑over‑year, while adjusted EPS beat expectations at $1.67.
These numbers demonstrate how Bristol Myers Squibb converts its business scale and diversified product lineup into stable financial performance, underpinning its dividend track record and long‑term shareholder value.
📱 In the MaxDividends snapshot, these numbers show how Bristol Myers Squibb converts its business scale and product‑diversity into stable earnings — exactly the kind of financial strength that underpins a solid dividend track record and long‑term shareholder value.
If you want to stay on top of your portfolio’s health, don’t forget to check in on the financials of the companies you’ve invested in. The better shape they’re in, the better your results will be. Keep an eye on their quarterly and annual reports to see how they’re performing.
The strongest and most stable companies tend to have a Financial Score of 80+, with the very best ones hitting 90+. If you see that score start to dip below 80, that’s your cue to consider jumping ship before things get worse.
👉 Learn More about Financial Score
Our Premium Members get access to a curated watchlist of 19,000 companies worldwide, all scored by our team on a regular basis. Companies like Bristol Myers Squibb are on that list, too.
Future Growth Prospects for Bristol Myers Squibb
Bristol Myers Squibb (BMY) is well-positioned for future growth through several key drivers:
Innovative Pipeline: Multiple late-stage programs, including milvexian for stroke prevention and admilparant for pulmonary fibrosis, could generate significant sales if approved.
New Product Launches: BMS aims to bring over 10 new medicines to market by 2030, while pursuing label expansions in oncology, immunology, and neuroscience.
Strategic Partnerships: Collaborations, such as its cancer drug partnership with BioNTech and AI-driven initiatives, accelerate drug development and expand capabilities.
Revenue Diversification: Growth portfolio products help offset potential declines from older drugs facing generic competition, ensuring more stable long-term revenue.
These factors collectively suggest that Bristol Myers Squibb is targeting sustained innovation and diversified revenue expansion, strengthening its long-term growth outlook.
Interesting Fact
Bristol Myers Squibb isn’t just a pharmaceutical giant — it played a key role in the development of the first FDA-approved immunotherapy for cancer.
Its drug Opdivo (nivolumab), approved in 2014, revolutionized cancer treatment by using the body’s own immune system to attack tumors, a breakthrough that transformed oncology worldwide.
What makes it particularly unusual is that Opdivo was developed from research originally funded for basic immune system studies, showing how decades of scientific exploration can unexpectedly lead to life-saving therapies
Competitors
1. Pfizer Inc (NYSE: PFE)
Financial Score: 95 / 99
Industry: Drug Manufacturers - General
Global pharmaceutical and biotech powerhouse: Pfizer develops, manufactures and markets medicines and vaccines for internal medicine, oncology, immunology, rare diseases and more.
2. Merck & Company Inc (NYSE: MRK)
Financial Score: 98 / 99
Industry: Drug Manufacturers - General
Global pharmaceutical & biotech leader: Merck develops, manufactures and markets a wide range of medicines, vaccines and biologics for human health — oncology, vaccines, cardiology, immunology — plus a substantial portfolio in animal-health and veterinary products
Final Thoughts
Bristol Myers Squibb has a long and proven record of dividend growth, with 17 consecutive years of increases, reflecting its commitment to returning value to shareholders.
The company maintains a strong dividend yield of 4.63 % and an annual payout of $2.52 per share, supported by stable free cash flow, solid profitability, and a diversified portfolio of medicines across oncology, immunology, cardiovascular disease, and more.
BMY’s robust pipeline and strategic partnerships provide resilience against patent expirations and market fluctuations, ensuring long-term growth potential alongside consistent dividend payments.
Bristol Myers Squibb may not offer explosive short-term growth, but for investors seeking steady dividends, scientific innovation, and a fundamentally strong, resilient business, BMY represents a compelling long-term option.
Why Invest in Bristol Myers Squibb?
Global biopharma leader: Bristol Myers Squibb develops and markets innovative medicines for serious diseases, including cancer, cardiovascular conditions, and immunological disorders, with a presence in over 60 countries.
Diversified product portfolio: Key therapies like Opdivo, Eliquis, and newer pipeline drugs provide balanced revenue streams and help mitigate risks from older products facing generic competition.
Innovation-driven growth: BMY invests heavily in R&D, advancing a robust pipeline of late-stage candidates in oncology, immunology, and neuroscience, supporting future revenue and long-term competitiveness.
Strong financial performance: In 2024, BMY generated $48.3 billion in revenue, demonstrating resilience and consistent profitability across its major franchises.
Clear growth trajectory: Strategic partnerships, label expansions, and upcoming product launches position Bristol Myers Squibb for continued growth in the coming years.
Market Value Today: Fairly Valued
Compare the P/E ratios of competitor companies to assess whether the stock you’re considering is overvalued. We calculate the average P/E among competitors as a benchmark.
If a company’s current P/E is 20% or more below the competitor average, it is considered undervalued.
If it is 20% or more above, it is considered overvalued.
The P/E ratio is calculated by dividing the market value per share by earnings per share (EPS).
Analysts Consensus
According to the latest analyst estimates, 14 analysts covering Bristol Myers Squibb (BMY) stock have a consensus rating of “Buy.” The average price target is $57.64, implying a potential 5.76 % upside from the current stock price. Analysts’ forecasts range widely, with the lowest target at $37 and the highest at $68, reflecting varying expectations about the company’s growth trajectory and market conditions.
This consensus indicates that, while there are risks, the majority of experts see moderate to strong potential for BMY over the next 12 months.
***
Everything you’ve just read about — the dividend intelligence, the quality filters, the structured selection process, the portfolio tracking, the income optimization — is fully integrated inside the MaxDividends App.
The App brings together our strategy, screening logic, risk controls, Dividend Eagles lists, top dividend ideas, and curated lists of the most undervalued high-quality dividend companies — all integrated with the Income Assistant in one structured environment. It’s where analysis turns into decisions, and decisions turn into measurable income.
Everything works together in one place, designed to make disciplined dividend investing clear, manageable, and repeatable over time.
If you want access to the full system — it begins inside the platform.
🔓 Request Free Early Access to the MaxDividends App 🔓
Unlock instant 🎁 access to the MaxDividends Income System & App, featuring our top undervalued dividend picks and the most promising dividend ideas for 2026.
To your wealth, MaxDividends Team